7 recruiting, 6 completed, 2 active not recruiting, 1 approved for marketing. 10 Phase 1, 4 Not applicable, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 5, Recruiting 4, Terminated 1 |
| Not applicable | 4 | Active not recruiting 2, Recruiting 2 |
| Phase 2 | 4 | Recruiting 2, Terminated 1, Unknown 1 |
Follow Solid Tumor, Unspecified, Adult: new trials by email Literature Review of Solid Tumor, Unspecified, Adult trials Research Report on Solid Tumor, Unspecified, Adult
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations Blood Sample, Tissue Sample, Excess fluid Sample - Solid Tumor, Solid Tumor, Adult | Withdrawn | University of California, San Francisco | 2026-08-31 | 2026-09-02 | ||
| A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products No additional intervention administered in this long term follow-up study - Solid Tumor Cancer, Solid Tumor, Unspecified, Adult | Enrolling by invitation | A2 Biotherapeutics Inc. | 400 | 2025-07-31 | 2026-05-20 | |
| AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors AD1208 - Solid Tumor, Adult, Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Avelos Therapeutics Inc. | 36 | 2025-03-11 | 2025-04-04 |
| A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. LXP1788 is administered intravenously via Port-A - Solid Tumor Malignancies, Cancer, Solid Cancers | Phase 1 | Recruiting | LaunXP Biomedical Co., Ltd. | 24 | 2024-12-31 | 2025-03-19 |
| The Safety and Dosimetry Study of 177Lu-LNC1004 Injection 177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004 Injection group 2 radionuclide therapy, 177Lu-LNC1004 Injection group 3 radionuclide therapy - Solid Tumor, Unspecified, Adult | Phase 1 | Completed | Yantai LNC Biotechnology Singapore PTE. LTD. | 11 | 2023-10-03 | 2025-09-08 |
| 68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors 68 Gallium -Fibroblast Activating Protein Inhibitor -46 Positron emission tomography / Computerized tomography - Solid Tumor, Unspecified, Adult | Phase 2 | Unknown | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 100 | 2023-08-21 | 2024-06-04 |
| Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors MPB-1734 - Solid Tumor, Unspecified, Adult | Phase 1 / Phase 2 | Recruiting | MegaPro Biomedical Co. Ltd. | 81 | 2022-03-08 | 2025-11-03 |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors Fruquintinib, Tislelizumab - Triple Negative Breast Cancer, Endometrial Cancer | Phase 1 / Phase 2 | Terminated | Hutchmed | 52 | 2021-08-09 | 2025-07-14 |
| Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values CONVO intervention - Solid Tumor, Solid Tumor, Adult | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 234 | 2021-06-18 | 2026-07-02 |
| Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein Determination of ATM alteration status. - Solid Tumor, Unspecified, Adult | Completed | Artios Pharma Ltd | 229 | 2021-05-28 | 2022-08-01 | |
| Gustave Roussy Cancer Profiling Biopsy - Solid Tumor, Unspecified, Adult | Not applicable | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 20000 | 2021-05-10 | 2026-02-06 |
| Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment Solid Tumor, Unspecified, Adult, Haematological Malignancy | Recruiting | Morten Ladekarl | 3000 | 2020-07-01 | 2024-01-31 | |
| An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors INV-1120, Pembrolizumab - Cancer, Solid Tumor, Adult | Phase 1 | Recruiting | Shenzhen Ionova Life Sciences Co., Ltd. | 78 | 2020-06-26 | 2026-03-18 |
| Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors Single Arm - Solid Tumor, Unspecified, Adult, Lymphoma | Phase 1 | Completed | Cytosite Biopharma Inc. | 13 | 2020-06-16 | 2026-10-13 |
| RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors RLY-1971 - Solid Tumor, Unspecified, Adult | Phase 1 | Completed | Hoffmann-La Roche | 56 | 2020-02-04 | 2023-01-31 |
| Psychotherapy Intervention for Latinos With Adv Cancer Meaning Centered Psychotherapy for Latinos, Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale, Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients - Solid Tumor, Solid Tumor, Adult | Not applicable | Active not recruiting | Memorial Sloan Kettering Cancer Center | 117 | 2019-01-01 | 2026-10-08 |
| A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Domvanalimab, Zimberelimab - Solid Tumor, Unspecified, Adult | Phase 1 | Completed | Arcus Biosciences, Inc. | 75 | 2018-09-12 | 2025-02-04 |
| Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Rucaparib, Irinotecan - Solid Tumor, Unspecified, Adult | Phase 1 | Completed | Pamela Munster | 22 | 2018-01-12 | 2021-03-04 |
| Psychotherapy Intervention for Latinos With Advanced Cancer Meaning Centered Psychotherapy for Latinos, Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale, Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients - Solid Tumor, Solid Tumor, Adult | Not applicable | Active not recruiting | Memorial Sloan Kettering Cancer Center | 177 | 2015-04-20 | 2026-10-08 |
| Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor MCLA-128 - NRG1 Fusion, Pancreatic Cancer | Approved for marketing | Merus B.V. | 2025-05-20 |
Neoplasms (6) · Carcinoma, Renal Cell (3) · Colorectal Neoplasms (3) · Pancreatic Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Head and Neck Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Hematologic Neoplasms (1) · Kidney Neoplasms (1) · Lymphoma (1) · Mesothelioma (1)
Neoplasms by Site (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Skin and Connective Tissue Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Adenocarcinoma (3) · Breast Diseases (3) · Carcinoma (3) · Colonic Diseases (3) · Endocrine Gland Neoplasms (3)
Biopsy (1) · Blood Specimen Collection (1) · HMPL-013 (1) · Histocompatibility Testing (1) · Irinotecan (1) · Tomography, X-Ray Computed (1) · pembrolizumab (1) · rucaparib (1) · tislelizumab (1) · zenocutuzumab (1) · zimberelimab (1)
Memorial Sloan Kettering Cancer Center (3) · A2 Biotherapeutics Inc. (1) · Arcus Biosciences, Inc. (1) · Artios Pharma Ltd (1) · Avelos Therapeutics Inc. (1) · Cytosite Biopharma Inc. (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hoffmann-La Roche (1) · Hutchmed (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · LaunXP Biomedical Co., Ltd. (1) · MegaPro Biomedical Co. Ltd. (1) · Merus B.V. (1) · Morten Ladekarl (1) · Pamela Munster (1)
United States (11) · Taiwan (3) · Puerto Rico (2) · Australia (1) · Denmark (1) · France (1) · Italy (1) · Singapore (1) · South Korea (1) · United Kingdom (1)
Devika Jutagar, PhD (2) · Antoine Italiano, MD PhD (1) · Colin G Miller, PhD (1) · Eric Ng, MD (1) · Judith Nelson, MD (1) · Melissa Johnson, MD (1) · Morten Ladekarl, MD, DMSCi (1) · Muh-Hwa Yang, MD (1) · Pamela Munster, MD (1) · Varun Monga, MBBS (1) · William Schelman, MD, PhD (1)
PMID 36862966, PMID 37897866, PMID 38815178, PMID 38865673, PMID 39589242, PMID 41123648